{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "bêta-Alanine : Questions médicales les plus fréquentes",
"headline": "bêta-Alanine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les bêta-Alanine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-16",
"dateModified": "2025-03-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "bêta-Alanine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Alanine",
"url": "https://questionsmedicales.fr/mesh/D000409",
"about": {
"@type": "MedicalCondition",
"name": "Alanine",
"code": {
"@type": "MedicalCode",
"code": "D000409",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.125.042"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Acide pantothénique",
"alternateName": "Pantothenic Acid",
"url": "https://questionsmedicales.fr/mesh/D010205",
"about": {
"@type": "MedicalCondition",
"name": "Acide pantothénique",
"code": {
"@type": "MedicalCode",
"code": "D010205",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.125.042.070.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "bêta-Alanine",
"alternateName": "beta-Alanine",
"code": {
"@type": "MedicalCode",
"code": "D015091",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Bryan Saunders",
"url": "https://questionsmedicales.fr/author/Bryan%20Saunders",
"affiliation": {
"@type": "Organization",
"name": "Applied Physiology and Nutrition Research Group, Rheumatology Division, Faculdade de Medicina FMUSP, School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Eimear Dolan",
"url": "https://questionsmedicales.fr/author/Eimear%20Dolan",
"affiliation": {
"@type": "Organization",
"name": "Applied Physiology and Nutrition Research Group, Rheumatology Division, Faculdade de Medicina FMUSP, School of Physical Education and Sport, University of São Paulo, São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Bruno Gualano",
"url": "https://questionsmedicales.fr/author/Bruno%20Gualano",
"affiliation": {
"@type": "Organization",
"name": "Applied Physiology and Nutrition Research Group, School of Physical Education and Sport; Rheumatology Division; Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, SP, BR, University of São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Marcelo Papoti",
"url": "https://questionsmedicales.fr/author/Marcelo%20Papoti",
"affiliation": {
"@type": "Organization",
"name": "University of São Paulo, Medicine University of Ribeirão Preto (FMRP-USP), Ribeirão Preto, São Paulo, Brazil."
}
},
{
"@type": "Person",
"name": "Craig Sale",
"url": "https://questionsmedicales.fr/author/Craig%20Sale",
"affiliation": {
"@type": "Organization",
"name": "Musculoskeletal Physiology Research Group, Sport, Health and Performance Enhancement Research Centre, Nottingham Trent University, United Kingdom."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Recovering high value-added anthocyanins from blueberry pomace with ultrasound-assisted extraction.",
"datePublished": "2022-10-13",
"url": "https://questionsmedicales.fr/article/36277868",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.fochx.2022.100476"
}
},
{
"@type": "ScholarlyArticle",
"name": "Value Coefficient of Polyethylene Fiber Soil Embankment Slope Based on Response Surface Analysis.",
"datePublished": "2022-10-13",
"url": "https://questionsmedicales.fr/article/36297873",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/polym14204295"
}
},
{
"@type": "ScholarlyArticle",
"name": "Technoeconomic Feasibility of a Sunflower Husk Fast Pyrolysis Value Chain for the Production of Advanced Biofuels.",
"datePublished": "2022-10-12",
"url": "https://questionsmedicales.fr/article/36366752",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.energyfuels.2c01594"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Value of Metagenomic Next-Generation Sequencing in Leishmaniasis Diagnosis: A Case Series and Literature Review.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36438623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/ofid/ofac511"
}
},
{
"@type": "ScholarlyArticle",
"name": "Application Value of Management Model Based on \"Zero Tolerance\" Concept in Pressure Ulcer Management.",
"datePublished": "2022-10-10",
"url": "https://questionsmedicales.fr/article/36262118",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/6792584"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Acides aminés",
"item": "https://questionsmedicales.fr/mesh/D000596"
},
{
"@type": "ListItem",
"position": 4,
"name": "Alanine",
"item": "https://questionsmedicales.fr/mesh/D000409"
},
{
"@type": "ListItem",
"position": 5,
"name": "bêta-Alanine",
"item": "https://questionsmedicales.fr/mesh/D015091"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : bêta-Alanine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur bêta-Alanine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur bêta-Alanine",
"description": "Comment diagnostiquer une carence en bêta-alanine ?\nQuels tests peuvent évaluer les niveaux de bêta-alanine ?",
"url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Reference+Values&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur bêta-Alanine",
"description": "Quels sont les symptômes d'une supplémentation excessive en bêta-alanine ?\nLa bêta-alanine cause-t-elle des effets secondaires ?",
"url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Reference+Values&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur bêta-Alanine",
"description": "Comment prévenir une carence en bêta-alanine ?\nLes sportifs doivent-ils se supplémenter en bêta-alanine ?",
"url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Reference+Values&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur bêta-Alanine",
"description": "La bêta-alanine est-elle utilisée pour traiter des maladies ?\nComment la bêta-alanine améliore-t-elle la performance ?",
"url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Reference+Values&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur bêta-Alanine",
"description": "Quelles complications peuvent survenir avec une surconsommation ?\nLa bêta-alanine peut-elle interagir avec d'autres médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Reference+Values&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur bêta-Alanine",
"description": "Qui est à risque de carence en bêta-alanine ?\nLes athlètes d'endurance ont-ils besoin de plus de bêta-alanine ?",
"url": "https://questionsmedicales.fr/mesh/D015091?mesh_terms=Reference+Values&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une carence en bêta-alanine ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de test spécifique; une évaluation des symptômes et des apports alimentaires est nécessaire."
}
},
{
"@type": "Question",
"name": "Quels tests peuvent évaluer les niveaux de bêta-alanine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses sanguines peuvent mesurer les niveaux d'acides aminés, y compris la bêta-alanine."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une supplémentation excessive en bêta-alanine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une supplémentation excessive peut provoquer des picotements, des démangeaisons ou des rougeurs."
}
},
{
"@type": "Question",
"name": "La bêta-alanine cause-t-elle des effets secondaires ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires comme des picotements peuvent survenir, mais ils sont généralement bénins."
}
},
{
"@type": "Question",
"name": "Comment prévenir une carence en bêta-alanine ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée incluant des sources de protéines peut prévenir une carence."
}
},
{
"@type": "Question",
"name": "Les sportifs doivent-ils se supplémenter en bêta-alanine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les sportifs peuvent bénéficier d'une supplémentation pour améliorer leur endurance et performance."
}
},
{
"@type": "Question",
"name": "La bêta-alanine est-elle utilisée pour traiter des maladies ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle n'est pas un traitement médical, mais un complément pour améliorer la performance sportive."
}
},
{
"@type": "Question",
"name": "Comment la bêta-alanine améliore-t-elle la performance ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle augmente les niveaux de carnosine dans les muscles, retardant la fatigue lors d'exercices intenses."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une surconsommation ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surconsommation peut entraîner des troubles gastro-intestinaux et des picotements."
}
},
{
"@type": "Question",
"name": "La bêta-alanine peut-elle interagir avec d'autres médicaments ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des interactions sont possibles; il est conseillé de consulter un professionnel de santé."
}
},
{
"@type": "Question",
"name": "Qui est à risque de carence en bêta-alanine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes ayant une alimentation pauvre en protéines ou végétalienne peuvent être à risque."
}
},
{
"@type": "Question",
"name": "Les athlètes d'endurance ont-ils besoin de plus de bêta-alanine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent avoir besoin de plus de bêta-alanine pour améliorer leur performance et récupération."
}
}
]
}
]
}
Food waste is a potential source to replace fresh materials for obtaining functional ingredients. Blueberry pomace contains considerable amounts of anthocyanins. In this study, we investigated ultraso...
The utilization of polymers can strengthen soil, but at a high price. In this study, value coefficients were proposed to evaluate the cost-effectiveness of fiber-reinforced roadbeds, and the effects o...
Biofuels are required to reach the target set out by the European Commission's Transport mandate in the RED II (Renewable Energy Directive) for 2020-2030. To avoid indirect land use change, waste biom...
Leishmaniasis is a zoonotic disease caused by...
The study participants were 7 metagenomic next-generation sequencing (mNGS)-diagnosed patients with leishmaniasis who could not be diagnosed using conventional methods. Clinical data were retrospectiv...
A total of 7 patients with recurrent fever, pancytopenia, and significant splenomegaly were included in this study. Only 3 individuals tested positive for rK39. Two individuals, 1 of whom was HIV-posi...
mNGS could be used to identify leishmaniasis, particularly in patients who are difficult to diagnose using conventional approaches....
Pressure injuries are the most prevalent health problem worldwide. Improving the quality of hospital pressure injury management is an important indicator to improve the quality of hospital management....
To explore the application value of the management model centered on the concept of "zero tolerance" in the management of pressure ulcers (PU)....
The effects of conventional management mode and management mode centered on the concept of "zero tolerance" on PU patients and nursing staff were retrospectively analyzed. The patients were evaluated ...
When comparing the conditions of patients under different management modes, it was found that the "zero tolerance" management mode can improve the comfort and quality of life of patients during hospit...
Standardized management of PU patients with the concept of "zero tolerance" as the core can improve the health status and quality of life of patients, promote wound healing, and improve the satisfacti...
Cuproptosis is a type of programmed cell death that is involved in multiple physiological and pathological processes, including cancer. We constructed a prognostic cuproptosis-related long non-coding ...
RNA-seq and clinical data for AML patients were acquired from The Cancer Genome Atlas (TCGA) database. The cuproptosis-related prognostic lncRNAs were identified by co-expression and univariate Cox re...
Five hundred and three lncRNAs related to 19 CRGs in AML samples from the TCGA database were obtained, and 21 differentially expressed lncRNAs were identified based on the 2-year overall survival (OS)...
A cuproptosis-related lncRNA signature was established to predict the prognosis and inform on potential therapeutic strategies for AML patients....
Echocardiographic-determined left ventricular mass index (LVMI) provides quantitative information on left-ventricular structure. However, its prognostic value on light-chain (AL) amyloidosis has not b...
We included 99 patients with newly diagnosed AL amyloidosis between July 2013 and March 2022. Clinical features and echocardiographic parameters were collected....
LVMI ≥113.4 g/m...
LVMI is a reliable prognostic indicator of survival. A cut-off of LVMI (113.4 g/m...
As previously reported, impairment of left ventricular global longitudinal strain (LVGLS) is associated with myocardial fibrosis, arrhythmias, and heart failure in hypertrophic cardiomyopathy (HCM) pa...
This study aimed to estimate the association between LVGLS measured by echocardiography and major adverse cardiovascular events (MACE) in patients with HCM....
Pubmed, Embase, Scopus, and Cochrane Library databases were systematically searched for evaluating the difference of LVGLS between MACE and non-MACE and the relevance of LVGLS and MACE in HCM patients...
A total of 13 studies reporting 2441 HCM patients were included in this meta-analysis. Absolute value of LVGLS was lower in the group of HCM with MACE (MD = 2.74, 95% CI: 2.50-2.99, p < .001; I...
The meta-analysis suggested that impaired LVGLS was associated with poor prognosis in HCM patients....
Lactate levels have been recognized as a reliable tool for monitoring critically ill patients requiring venoarterial extracorporeal membrane oxygenation (VA ECMO) or venovenous extracorporeal membrane...
Patient demographics, ECMO duration, 30-day mortality, lactate values and lactate clearance at 24, 48 and 72 h from ECMO initiation of patients supported with VV and VA ECMO at Silesian Centre for Hea...
The study comprised 91 adult patients, Mortality in the first 30 days from initiation of VV and VA ECMO was 39% and 66%, respectively. Lactate levels were significantly higher in non-survivors that re...
This results emphasized the importance of lactate levels below 2.0 mmol/L at 72 h from both VV and VA ECMO initiation....
A significant amount of electronic documents have been produced as a result of the quick advancements in computer and network technology as well as the ongoing promotion of e-government, and the amoun...